Supplementary Materials

Supplementary Material for:

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Jim Nolan, Elaine Cadogan, Jim Murray, Rajesh Odedra, John Foster, Peter A. Hall, Susan Low, Paula Taylor, Rebecca Ellston, Urszula M. Polanska, Joanne Wilson, Colin Howes, Aaron Smith, Richard J. A. Goodwin, John G. Swales, Nicole Strittmatter, Zoltán Takáts, Anna Nilsson, Per Andren, Dawn Trueman, Mike Walker, Corinne L. Reimer, Greg Troiano, Donald Parsons, David De Witt, Marianne Ashford, Jeff Hrkach, Stephen Zale,* Philip J. Jewsbury,* Simon T. Barry*

*Corresponding author. E-mail: ucgasmg{at}ucl.ac.uk

Published 10 February 2016, Sci. Transl. Med. 8, 325ra17 (2016)
DOI: 10.1126/scitranslmed.aad2355

This PDF file includes:

  • Methods
  • Fig. S1. PD of AZD2811 nanoparticles in vivo in SW620 tumor xenograft models.
  • Fig. S2. Total nucleated cells from bone marrow in nude rats.
  • Fig. S3. MS reveals relative abundance of [M+H]+ metabolite.
  • Fig. S4. Process flow diagram for the generation of Accurin nanoparticles.
  • Table S1. AZD2811 solubility characteristics.
  • Table S2. Characteristics of AZD2811 nanoparticles produced during formulation screening.
  • Table S3. LC-MS/MS parameters.
  • Table S4. Optimized parameters for MS analyses.

[Download PDF]